News Tag: 2023 newsletters
Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-positive Salivary Gland Cancer (NRG-HN010)
Read More
Circulating Tumor DNA: One of Our Newest Tools for Managing Solid Tumors
Read More
NRG-BR008 (“HERO”): A Phase III Randomized Trial Seeking to Optimize Use of Radiotherapy in Patients with Early-Stage, Low Risk, HER2-Positive Breast Cancer
Read More
FORTE Study News: It’s Colorectal Cancer Awareness Month!
Read More
Protocol Support Committee (PSC) Column: NRG Oncology PSC 2023 Winter Meeting Wrap Up
Read More
Initial Report on Establishing Working Groups within the Head and Neck Cancer Committee
Read More
FORTE Study Update: Participant Travel Allowance
Read More
Set Up for Success – Coordinating RECIST 1.1: A Community Hospital Perspective
Read More
#FORTEStudy Workshop
Read More
NRG Innovations Continue in Cancer Care Delivery Research
Read More